GLP-1 Receptor Agonist By Product Type (Short-acting GLP-1 receptor agonists {Exenatide, Lixisenatide}, Long-acting GLP-1 receptor agonists {Dulaglutide, Semaglutide, Albiglutide, Liraglutide}), By Application (Type 2 Diabetes Management, Weight Management, Cardiovascular Disease Risk Reduction, Others), By Delivery Mode (Injectable, Oral, Transdermal, Other), By End-User ( Hospitals and Clinics, Retail and Online Pharmacies, Specialty Diabetes Care Centers, Research and Academic Institutions, Other), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

By Product Type

• Short-acting GLP-1 receptor agonists
  • Exenatide
  • Lixisenatide
• Long-acting GLP-1 receptor agonists
  • Dulaglutide
  • Semaglutide
  • Albiglutide
  • Liraglutide

 By Application

• Type 2 Diabetes Management
• Weight Management
• Cardiovascular Disease Risk Reduction
• Others

By Delivery Mode

• Injectable
• Oral
• Transdermal
• Other

By End-User

• Hospitals and Clinics
• Retail and Online Pharmacies
• Specialty Diabetes Care Centers
• Research and Academic Institutions
• Other

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of the Middle East & Africa

List of Companies:

• Novo Nordisk
• Eli Lilly and Company
• Sanofi
• AstraZeneca
• Boehringer Ingelheim
• Pfizer
• Amgen
• Oramed Pharmaceuticals
• Intarcia Therapeutics
• Evecxia Therapeutics
• Hanmi Pharmaceuticals
• Chugai Pharmaceutical
• Altimmune
• Zealand Pharma
• Viatris
• Merck & Co.
• Roche
• TheracosBio